Search Results - Ian Ford

Refine Results
  1. 1
    Pragmatic Trials

    Pragmatic Trials by Ian Ford, John Norrie

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    Total Ischaemic Burden European Trial (TIBET): Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina

    Total Ischaemic Burden European Trial (TIBET): Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angi... by Henry J. Dargie, Ian Ford, Kim Fox

    Published 1996
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Effect of Apomorphine on the Relationship between Local Cerebral Glucose Utilization and Local Cerebral Blood Flow (with an Appendix on its Statistical Analysis)

    Effect of Apomorphine on the Relationship between Local Cerebral Glucose Utilization and Local Cerebral Blood Flow (with an Appendix on its Statistical Analysis) by James McCulloch, Paul A. Kelly, Ian Ford

    Published 1982
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Mortality in heart failure: clinical variables of prognostic value.

    Mortality in heart failure: clinical variables of prognostic value. by John G.F. Cleland, Henry J. Dargie, Ian Ford

    Published 1987
    Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Are Routinely Collected NHS Administrative Records Suitable for Endpoint Identification in Clinical Trials? Evidence from the West of Scotland Coronary Prevention Study

    Are Routinely Collected NHS Administrative Records Suitable for Endpoint Identification in Clinical Trials? Evidence from the West of Scotland Coronary Prevention Study by Sarah Barry, Eleanor Dinnett, Sharon Kean, Allan Gaw, Ian Ford

    Published 2013
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Long-Term Safety and Efficacy of Lowering Low-Density Lipoprotein Cholesterol With Statin Therapy

    Long-Term Safety and Efficacy of Lowering Low-Density Lipoprotein Cholesterol With Statin Therapy by Ian Ford, Heather Murray, Colin McCowan, Chris J. Packard

    Published 2016
    Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    The Total Ischaemic Burden European Trial (TIBET): Effects of atenolol, nifedipine SR and their combination on the exercise test and the total ischaemic burden in 608 patients with stable angina

    The Total Ischaemic Burden European Trial (TIBET): Effects of atenolol, nifedipine SR and their combination on the exercise test and the total ischaemic burden in 608 patients with... by Kim Fox, Hugh Mulcahy, I. Findlay, Ian Ford, Henry J. Dargie

    Published 1996
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Rationale and design of a randomized, double‐blind, placebo‐controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I<sub>f</sub> Inhibitor Ivabradine Trial (SHIFT)

    Rationale and design of a randomized, double‐blind, placebo‐controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I<sub>f</... by Karl Swedberg, Michel Komajda, Michael Böhm, Jeffrey Borer, Ian Ford, Luigi Tavazzi

    Published 2009
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina

    Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina by Jean‐Claude Tardif, Ian Ford, Michał Tendera, Martial G. Bourassa, Kim Fox

    Published 2005
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    High Dose Atorvastatin Associated with Increased Risk of Significant Hepatotoxicity in Comparison to Simvastatin in UK GPRD Cohort

    High Dose Atorvastatin Associated with Increased Risk of Significant Hepatotoxicity in Comparison to Simvastatin in UK GPRD Cohort by Alan T. Clarke, P. Johnson, Gillian C. Hall, Ian Ford, Peter R. Mills

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial

    Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina... by Kim Fox, Ian Ford, Philippe Gabríel Steg, Michał Tendera, Michele Robertson, Roberto Ferrari

    Published 2009
    Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Effects on Outcomes of Heart Rate Reduction by Ivabradine in Patients With Congestive Heart Failure: Is There an Influence of Beta-Blocker Dose?

    Effects on Outcomes of Heart Rate Reduction by Ivabradine in Patients With Congestive Heart Failure: Is There an Influence of Beta-Blocker Dose? by Karl Swedberg, Michel Komajda, Michael Böhm, Jeffrey Borer, Michele Robertson, Luigi Tavazzi, Ian Ford

    Published 2012
    Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial

    Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial by Michel Komajda, Luigi Tavazzi, Bernard Francq, Michael Böhm, Jeffrey Borer, Ian Ford, Karl Swedberg

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study

    Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study by Luigi Tavazzi, Karl Swedberg, Michel Komajda, Michael Böhm, Jeffrey Borer, Mitja Lainščak, Ian Ford

    Published 2013
    Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    Top ten risk factors for morbidity and mortality in patients with chronic systolic heart failure and elevated heart rate: The SHIFT Risk Model

    Top ten risk factors for morbidity and mortality in patients with chronic systolic heart failure and elevated heart rate: The SHIFT Risk Model by Ian Ford, Michele Robertson, Michel Komajda, Michael Böhm, Jeffrey Borer, Luigi Tavazzi, Karl Swedberg

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    Ivabradine in Stable Coronary Artery Disease without Clinical Heart Failure

    Ivabradine in Stable Coronary Artery Disease without Clinical Heart Failure by Kim Fox, Ian Ford, Philippe Gabríel Steg, Jean‐Claude Tardif, Michał Tendera, Roberto Ferrari

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Bradycardia and atrial fibrillation in patients with stable coronary artery disease treated with ivabradine: an analysis from the SIGNIFY study

    Bradycardia and atrial fibrillation in patients with stable coronary artery disease treated with ivabradine: an analysis from the SIGNIFY study by Kim Fox, Ian Ford, Philippe Gabríel Steg, Jean‐Claude Tardif, Michał Tendera, Roberto Ferrari

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post‐hoc analysis of <scp>SHIFT</scp>

    Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post‐hoc analysis of <scp>SHIFT</scp> by Michel Komajda, Luigi Tavazzi, Karl Swedberg, Michael Böhm, Jeffrey Borer, Aurélie Moyne, Ian Ford

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta‐analysis

    Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta‐analysis by Michel Komajda, Michael Böhm, Jeffrey Borer, Ian Ford, Luigi Tavazzi, Matthieu Pannaux, Karl Swedberg

    Published 2018
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  20. 20
    Effect of Combining Ivabradine and β-Blockers: Focus on the Use of Carvedilol in the SHIFT Population

    Effect of Combining Ivabradine and β-Blockers: Focus on the Use of Carvedilol in the SHIFT Population by Edimar Alcides Bocchi, Michael Böhm, Jeffrey Borer, Ian Ford, Michel Komajda, Karl Swedberg, Luigi Tavazzi

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: